

REFERENCES

1. Collier L, Oxford J. The alphaherpesviruses: herpes simplex and varicella-zoster. In: Collier L, Oxford J, eds. *Human Virology*. 2nd ed. New York: Oxford University Press, 2000; 135-42.
2. Dwyer DW, Cunningham AL. Herpes simplex and varicella-zoster virus infection. *MJA* 2002; 177(5): 267-73.
3. White DO, Fenner FJ. *Medical Virology*: 4th ed. San Diego: Academic Press, 1994.
4. The homepage of National AIDS Treatment Information Project, established with a grant from the Henry J. Kaiser family foundation located at Beth ISFAEL, DEACONESS MEDICAL CENTER. Herpes simplex infection ("Herpes"). 2002. [ONLINE] <http://www.uq.edu.au/vdu/HSV.htm> (visited 25/12/02).
5. พิไลพันธ์ พุทธิวัฒน์ และคณะ. *Human herpesviruses*. กรุงเทพฯ : สำนักพิมพ์อักษรสมัย, 2538.
6. Whitley RJ. Herpesviridae. In: Fields BN, Knipe DM, Howley et al, eds. *Fields Virology*. 3rd ed. Philadelphia: Lippincott-Rave Publishers, 1996; 2297-342.
7. The homepage of the newmours foundation. 2002. Herpes Simplex. [ONLINE] <http://www.kidshealth.org/parent/infec/std/herpes.htm> (visited 24/12/02).
8. Thouvenot D, Najioullah F. Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), eds. *Rev Prat* 1999 Dec 15; 49(20): 2203-7.

9. The homepage of Department of Medicine Microbiology, University of Cape Town. 1995. The roles were prepared by Diana Hardie For Virology Lectures to 3rd Year. [ONLINE] <http://www.uct.ac.za/dets/mmi/jmoodie/hsv.2.htm> (visited 10/06/01).
10. The homepage of princeton university health services. 2000. Herpes Simplex Virus. [ONLINE] <http://www.pimceton.eud/pushSECH/hsv.htm> (visited 10/06/01).
11. Tebas P, Stabell EC, Olivo PD. Antiviral susceptibility testing with a cell line which express β -galactosidase after infection with herpes simplex. *Antimicrob Agents Chemother* 1995 June; 39(6): 1287-91.
12. Schmit I, Boivin G. Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. *J infect Dis* 1999; 180: 487-90.
13. Lennette EH, Smith TF. *Laboratory diagnosis of infection*. 3rd ed. New York: Marcel Dekker, Inc, 1999.
14. Abadi J, Acyclovir: in brief. *Pediatrics in Review* 1997 Feb; 18 (2): 70-1.
15. O'Brien JJ, Campoli-Richard DM. Acyclovir: an undated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. *Drugs* 1989; 37: 233-309.
16. Sack SL. Treatment of herpes genitalis. In: Clereq ED, ed. *Clinical use of antiviral drugs*. Boston: Martinus Nijhoff Publishing, 1998; 87-114.
17. Sasadeusz J, Sack SL. Systemic antivirals in herpes infections. In: Maddin SM, McLean DI, eds. *Dermatologic clinics*, vol 11. Philadelphia: W.B. Saunders Co, 1992; 171-85.

18. Shepp DH, Newton BA, Dandliker PS, Floumoy N, Meyers JD. Oral acyclovir therapy for mucocutaneous herpes simplex virus infection in immunocompromised marrow transplant recipients. *Ann Intern Med* 1985; 102: 783-5.
19. Wade JC, Newton B, Floumoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. *Ann Intern Med* 1984; 100: 825-8.
20. Roizman B, Whitley RJ, Lopes C. *The human Herpesviruses*. 1st ed. New York: Raven Press, 1993.
21. The homepage of Herpes Online Personal Empowerment & Support. 2001. Herpesite Herpes support Online. [ONLINE] <http://www.members.aol.com/herpesite/test.html#treat> (visited 24/12/02).
22. Dorsky DI, Crumpacker CS. Drugs five years later: acyclovir. *Ann Intern Med* 1987; 107: 857-74.
23. Gnann JW Jr, Barton NH, Whitley RJ. Acyclovir-mechanism of action, pharmacokinetic, safety and clinical applications. Evaluations of new drugs. *Pharmacotherapy* 1983; 3: 275-83.
24. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action an anti-herpetic agent, 9-(2-hydroxyethoxymethyl) guanine. *Proc Natl Acad Sci USA* 1977; 74: 5716-20.
25. Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ, Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. *Nature* 1978; 272: 583-5.

26. Field AK, Biron KK. "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. *Clin Microbiol Rev* 1994; 7: 1-13.
27. Nugier F, Collin JN, Aymard M, Langlois M. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. *J Med Virol* 1992; 36: 1-12.
28. Safrin S, Elbeik T, Mills J. A rapid screen test for *in vitro* susceptibility of clinical herpes simplex virus isolates. *J Infect Dis* 1994; 169: 879-82.
29. Suzutani T, Koyano S, Takada M, Yoshida I, Azuma M. Analysis of the relationship between cellular thymidine kinase activity and virulence of thymidine kinase-negative herpes simplex virus type 1 and 2. *Microbiol Immunol* 1995; 39(10): 787-94.
30. Erlich KS, Milks J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with acquired immunodeficiency syndrome. *N Engl J Med* 1989; 320: 293-6.
31. Safrin S, Assaykeen T, Follansbee S, Mills J. Foscarnet therapy for Acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients : preliminary data. *J Infect Dis* 1990; 161: 1078-84.
32. Safrin S, Crumpackar C, Chais P, et al. A controlled trial complain foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in acquired immunodeficiency syndrome. *N Engl J Med* 1991; 325: 551-5.
33. Hill EL, Hunter GA, Ellis MN. *In vitro* and *in vivo* characterization of herpes simplex virus clinical isolates recovered from patients infected with immunodeficiency virus. *Antimicrob Agents Chemother* 1991; 35: 2322-8.

34. Ellis MN, Keller PM, Fyfe JA, et al. Clinical isolate of herpes simplex virus type-2 that induces a thymidine kinase with altered substrate specificity. *Antimicrob Agents Chemother* 1987; 31: 1117-25.
35. Darby G, Fied HJ. Altered substrate specificity of herpes simplex virus thymidine kinase confer acyclovir-resistance. *Nature* 1981; 289: 81-3.
36. Kost RG, Hill EL, Tigges M, Straus SE. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. *N Engl J Med* 1993; 329: 1777-82.
37. Martin JL, Ellis MN, Keller PM, et al. Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates. *Antimicrob Agents Chemother* 1985; 28: 181-7.
38. Coen DM, Schaffer PA. Two distinct loci confer resistant to acycloguanosine in herpes simplex virus type 1. *Proc Natl Acad Sci USA* 1980; 77: 2265-9.
39. Gaudreau AE, Hill E, Balfour HH Jr, Erice A, Boivin G. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. *J Infect Dis* 1998; 178: 297-303.
40. Schnipper LE, Crumpacker CS. Resistant herpes simplex viruses to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. *Proc Natl Acad Sci USA* 1980; 77: 2270-3.
41. Birch CJ, Tachedjian G, Doherty RR, Hayes K, Gust ID. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from patient with the acquired immunodeficiency syndrome. *J Infect Dis* 1990; 162: 731-4.

42. Collins P, Larder BA, Oliver NM, Kemp S, Smith IW, Darby G. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. *J Gen Virol* 1989; 70: 375-82.
43. Parker AC, Craig JI, Collins P, Oliver N, Smith I. Acyclovir-resistant herpes simplex virus infection due to altered DNA polymerase. *Lancet* 1987; ii: 1461.
44. Sack SL, Wankiln RJ, Reece DE, Hicks KA, Tyler KL, Coen DM. Progress esophagitis from acyclovir-resistant herpes simplex, Clinical role for DNA polymerase mutants and viral heterogeneity?. *Ann Intern Med* 1989; 111: 893-9.
45. Balfour HH Jr. Resistance of herpes simplex to acyclovir. *Ann Intern Med* 1983; 83: 404-6.
46. Coen DM. General aspects of virus resistance with special reference of herpes simplex virus. *J Antimicrob Chemother* 1986; 18(Suppl B): 1-10.
47. Tebas P, Scholl D, Jolilick J, McHarg K, Arens M, Olivo PD. A rapid assay to screen for drug-resistant herpes simplex virus. *J Infect Dis* 1997 Aug; 177: 217-20.
48. Suzutani T, Saijo M, Nagamine M, Ogasawara M, Azuma M. Rapid phenotypic characterization method for herpes simplex virus and varicella-zoster virus thymidine kinase to screen for acyclovir-resistant viral infection. *J Clin Microb* 2000 May; 38(5): 1839-44.
49. Alberts, B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. *Molecular Biology of the Cell*. 3rd ed. New York: Garland Publishing, 1994.
50. Horsburgh BC, Chen SH, Hu A, Mulamba G, Burns WH, Coen DM. *Antiviral susceptibility testing: proposed standard M33-P*, i-34. National Committee for Clinical Laboratory Standards Wayne, Pa 2000.

51. Larder BA, Darby G. Virus drug-resistance: mechanisms and consequences. *Antiviral Res* 1984; 4: 1-42.
52. Darby G, Larder B, Inglis M. Evidence that the "active centre" of the herpes simplex virus. *J Gen Virol* 1986; 67: 753-8.
53. Morfin F, Souillet G, Bilger K, Ooka T, Aymard M, Thouvenot D. Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. *J Infect Dis* 2000; 177: 188-95.
54. Nugier F, Collins P, Larder B, Langlois M, Aymard M, Darby G. Herpes simplex virus isolated from an immunocompromised patient who failed to respond to acyclovir treatment express thymidine kinase with altered substrate specificity. *Antiviral Chemother* 1991; 2: 295-302.
55. Sasadeusz JJ, Tufaro F, Safrin S, et al. Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir. *J Virol* 1997; 71: 3872-8.
56. Hodinka R, Swierkosz VA, Lancaster D, et al. *Antiviral susceptibility testing. Proposed Standard M33-P*. National Committee for Clinical Laboratory Standards Wayne, Pa 2000; 20(22).
57. Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, School DR, Balfour HH. Herpes simplex virus resistant to acyclovir: A study in a tertiary care center. *Ann Intern Med* 1990; 112: 416-22.
58. Ashley RL. Herpes simplex virus type 1 and 2 In: Lennette EH, Smith TF. *Laboratory diagnosis of viral infections*. 3rd ed, New York: Marcel Dekker, 1999: 489-513.

59. Collin P, Oliver NM. Sensitivity monitoring of herpes simplex virus isolates from patients receiving acyclovir. *J Microb Chemo* 1986; 18(Suppl 8): 103-12.
60. Christophers J, Clayton J, Craske J, et al. Survey of resistance of herpes simplex virus to acyclovir in Northwest England. *Antimicrob Agents Chemother* 1998 Apr; 42(4): 868-72.
61. L'vov ND, Andronova VL, Leont'eva NA, Glaegov GA. Isolation of acyclovir-resistant strains of herpes simplex virus from clinical material. *Vopr Virusol* 1999; 44(6): 247-9.
62. Sarisky RT, Nguyen TT, Duffy KE, Wittrock RJ, Leary JJ. Difference in incidence of spontaneous mutations between herpes simplex virus type 1 and 2. *Antimicrob Agents Chemother* 2000 June; 44(6): 1524-9.
63. Baumann R. 2002. Virology hematology gene therapy PCR kids stuff E.M. [ONLINE] <http://www.uq.edu.au.vdv/HSV.htm> (visited 25/12/02).
64. Widy P. Herpes: history and classification. In: Kaplan AS, ed. *The herpesvirus*. New York: Academic Press, 1973; 1-25.
65. Nadelman CM, Newcomer VD. Herpes simplex virus infections: New treatment approaches make early diagnosis even more important. *Postgrad Med* 2000 March; 107(3): 189-200.
66. Beswick TS. The origin and use of DAO herpes. *Med Hist* 1962; 6: 214.
67. Metcalf JF, Koga J, Chatterjes S, Whitley RJ. Protection herpetic ocular disease by immunotherapy. *Intervirology* 1987; 185: 1-11.

68. Schneweiss KE. Untersuchungen zur typendifferenzierung des herpesvirus hominis. *Z Immuno-Forsch* 1962; 124: 24-8.
69. Nahmias Aj, Dowdle WR. Antigenic and biologic difference in herpesvirus hominis. *Prog Med Virol* 1968; 10:110-3.
70. Roizman B, Carmichael LE, Deinhardt F, et al. Herpesviridae: Definition, provision nomenclature and taxonomy, *Intervirology* 1981; 16: 201-17.
71. Kaufman RH, Gardner HL, Rawls WE, Dixon RE, Young RL. Clinical features of herpes genitalis. *Cancer Res* 1973; 33: 1446-51.
72. Franenkel –conrat H, Kimball PC, levy JA. *Virology* 2nd ed. New Jersey: Prentice-Hall, 1988.
73. Puals FP, Dowdle WR, A nomenclature of virus. *Prog Med Virol* 1982; 28: 208-21.
74. Plummer G. Serological comparison of the herpes virus. *Br J Exp Pathol* 1964; 45: 135- 1.
75. Kieff Ed, Hoyer B, Bachenheimer SL, Roizman B. Genetic relateness of type 1 and type 2 herpes simplex virus. *J Virol* 1972; 9: 738-45.
76. Roizman B, Furlong D. The replication of herpesviruses. In: Fancekel Conrat H, Wagner RR, eds. *Comprehensive Virology*. New York: Plenum, 1974; 229-403.
77. Becker Y, Dym H, Sarov I. Herpes simplex virus DNA. *Virology* 1968; 36: 184-92.

78. Kieff ED, Bachenheimer SL, Roizman B. Size, composition, and structure of the deoxyribonucleic acid of herpes simplex virus subtypes 1 and 2. *J Virol* 1971; 8: 125-32.
79. Plummer G, Goodheart CR, Henson D, Bowling CP. A comparative study of the DNA density and behavior in tissue cultures of fourteen different herpesviruses. *Virology* 1969; 39: 134-7.
80. Furlong D, Swift H, Roizman B. Arrangement of herpesvirus deoxyribonucleic acid in the core. *J Virol* 1972; 10: 1071-4.
81. Zhou ZH, Chen DH, Jakana J, et al. Visualization of tegument-capsid interactions and DNA in intact herpes simplex virus type 1 virions. *J Virol* 1999; 73: 3210-8.
82. McGroch DJ, Dalrymple MA, Davison AJ, et al. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. *J Gen Virol* 1988; 69: 1531-74.
83. Dolan A, Jamieson FE, Cunningham C, et al. The genome sequence of herpes simplex virus type 2. *J Virol* 1998; 72: 2010-21.
84. Wadsworth S, Jacob RJ, Roizman B. Anatomy of herpes simplex virus DNA. II. Size, composition, and arrangement of inverted terminal repetitions. *J Virol* 1975; 15: 1487-97.
85. Delius H, Clements JB. A partial denaturation map of herpes simplex virus type 1 DNA: Evidence for inversions of the unique DNA regions. *J Gen Virol* 1976; 33: 125-33.

78. Kieff ED, Bachenheimer SL, Roizman B. Size, composition, and structure of the deoxyribonucleic acid of herpes simplex virus subtypes 1 and 2. *J Virol* 1971; 8: 125-32.
79. Plummer G, Goodheart CR, Henson D, Bowling CP. A comparative study of the DNA density and behavior in tissue cultures of fourteen different herpesviruses. *Virology* 1969; 39: 134-7.
80. Furlong D, Swift H, Roizman B. Arrangement of herpesvirus deoxyribonucleic acid in the core. *J Virol* 1972; 10: 1071-4.
81. Zhou ZH, Chen DH, Jakana J, et al. Visualization of tegument-capsid interactions and DNA in intact herpes simplex virus type 1 virions. *J Virol* 1999; 73: 3210-8.
82. McGroch DJ, Dalrymple MA, Davison AJ, et al. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. *J Gen Virol* 1988; 69: 1531-74.
83. Dolan A, Jamieson FE, Cunningham C, et al. The genome sequence of herpes simplex virus type 2. *J Virol* 1998; 72: 2010-21.
84. Wadsworth S, Jacob RJ, Roizman B. Anatomy of herpes simplex virus DNA. II. Size, composition, and arrangement of inverted terminal repetitions. *J Virol* 1975; 15: 1487-97.
85. Delius H, Clements JB. A partial denaturation map of herpes simplex virus type 1 DNA: Evidence for inversions of the unique DNA regions. *J Gen Virol* 1976; 33: 125-33.

93. Gibson W, Roizman B. Proteins specified by of herpes simplex virus. VII. Characterization and composition of multiple capsid forms of subtypes 1 and 2. *J Virol* 1972; 10: 1044-52.
94. Reichman RC. Herpes simplex virus. In: Belshe RB, ed. *Human Virology*. Massachusetts: PS, 1984; 811-28.
95. Wagner EK. 2002. Herpes replication (HSV). [ONLINE]
<http://darwin.bio.uci.edu/~faculty/wagner/hsv4f.html> (visited 09/06/03).
96. Roizman B, Knipe DM. Herpes simplex viruses and their replications In: Knipe DM, Howley PM, eds. *Fundamental Virology*, 4th ed. Philadelphia: Lippincott williams & wilkins, 2001: 1141-83.
97. Fraser JW, Deatly AM, Mellerick MI, et al. Molecular biology of latent HSV-1. In: Lopez C, Roizman B, eds. *Human herpesvirus infections: Pathogenesis, diagnosis, and treatment*. New York: Raven, 1986; 39-54.
98. Mellerick DM, Fraser NW. Physical state of the latent herpes simplex virus genome in a mouse model system: Evidence suggesting an episomal state. *Virology* 1987; 158: 265-75.
99. Stevens JG, Wagner EK, Devi-Rao GB, et al. RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. *Science* 1987; 235: 1056-9.
100. Wagner EK. 2002. Latent infection by HSV. [ONLINE]
<http://darwin.bio.uci.edu/~faculty/wagner/hsv5f.html> (visited 9/06/03).
101. Fitzpatrick TB, et al. *Dermatology in general medicine*. 4th ed. New York: McGraw-Hill, 1993; 2531-47.

102. Spruance SL, Rea TL, Thoming C, et al. Penciclovir cream for the treatment of herpes simplex labialis: a randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. *JAMA* 1997; 277(17): 1373-9.
103. Habib T. *The diagnostic manual of herpesvirus infections*. Research Triangle Park, NC: Burroughs Wellcome Co, 1995.
104. Hayes RJ, Pujades Rodriguez MM, Obasi A, Mosha F, et al. Herpes simplex virus type 2 infection increases HIV incidence in rural Tanzania. Abstract of presentation to the ISSTD/IUSTI Conference, Berlin, Germany 24-27 June 2001. *Int J STD AIDS*; 12(suppl 2): 62-63.
105. Halioua B, Malkin JE. Epidemiology of genital herpes - recent advances. *Eur J Dermatol* 1999; 9(3): 177-84.
106. O'Farrell N. Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmes. *Sex Transm Infect* 1999; 75(6): 377-84.
107. Krone MR, Wald A, Tabet SR, Paradise M, Corey L, Celum CL. Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors. *Clin Infect Dis* 2000; 30 (2): 261-7.
108. Kamali A, Nunn AJ, Mulder DW, Van Dyck E, Dobbins JG, Whitworth JA. Seroprevalence and incidence of genital ulcer infection in a rural Ugandan population. *Sex Transm Infect* 1999; 75: 98-102.

109. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. *N Engl J Med* 1997; 337 (16): 1105-11.
110. Obasi A, Mosha F, Quigley M, et al. Antibody to herpes simplex virus type 2 as a marker of sexual risk behaviour in rural Tanzania. *J Infect Dis* 1999; 179 (1): 16-24.
111. Weiss HA, Buvé A, Robinson NJ, et al. Study group on heterogeneity of HIV epidemics in African Cities. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. *AIDS* 2001; 15 (suppl 4): S97-S108.
112. Ross JD, Smith IW, Elton RA. The epidemiology of herpes simplex types 1 and 2 infection of the genital tract in Edinburgh 1978-1991. *Genitourin Med* 1993; 381-3.
113. Sucato G, Wald A, Wakabayashi E, Vieira J, Corey L. Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region. *J Infect Dis* 1998; 177(4): 1069-72.
114. Crawford SA, Clover RD, Abell TD. Rimantadine prophylaxis in children: a follow-up study. *Pediatr Infect Dis J* 1988; 7: 379-83.
115. Hirsch MS, Swartz MN. Antiviral agents. *N Engl J Med* 1980; 302: 903-7.
116. Bacon TH, Levin MJ, Leary JS, Sarisky RT, Sutton D. Herpes simplex viral resistance to acyclovir and penciclovir after two decades of antiviral therapy. *Clin Microb Rev* 2003 : 16 (1); 114-28.

117. Furman PA, deMiranda F, St Clair MH, Elion GB. Metabolism of acyclovir in virus infected and uninfected cells. *Antimicrob Agents Chemother* 1981; 20: 518-24.
118. Keller PM, Fyfe JA, Beauchamp L. Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. *Biochem Pharmacol* 1981; 30: 3071-7.
119. Elion, GB. Mechanism of action and selectivity of acyclovir. *Am J Med* 1982; 73(1A): 7-13.
120. Hirsch MS, Kaplan JC, O'Aquila RT. Antiviral agents. In: Fields BN, Knipe DM, Howley PM, eds. *Fields' Virology*, 3rd ed. Philadelphia: Lippincott-Raven, 1996.
121. Hayden FG. Antiviral agents, In: Mandell GL, Bennet JE, Dolin R, eds. *Principles and practice of Infection Diseases*. 4th ed. New York: Churchill Livingstone, 1995; 441-50.
122. Rearden JE, Spector T. Herpes simplex virus type I DNA polymerase: mechanism of inhibition by acyclovir triphosphate. *J Biol Chem* 1989; 264: 7405-11.
123. Rearden JE, Spector T. Ayclovir: mechanism of antiviral action and potentiation by ribonucleotide reductase inhibitors. *Adv Pharmacol* 1992; 221: 1-27.
124. Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. *Antimicrob Agents Chemother* 1992; 36: 2747-57.

125. Isley DD, Lee SH, Miller WH, Kuchta RD. Acyclic guanosine analogs inhibit DNA polymerase α , δ , and ϵ with very different potencies and have unique mechanism of action. *Biochemistry* 1995; 34: 2504-10.
126. Lowe DM, Alderton WK, Ellis MR, et al. Mode of action of (R) -9-[4-hydroxymethyl) butyl]guanine against herpesviruses. *Antimicrob Agents Chemother* 1995; 39: 1802-8.
127. Crumacker CS, Schipper LE, Marlowe SI, Kowalsky PN, Hershey BJ, Levin MJ. Resistance to antiviral drug of herpes simplex virus isolated from a patient treated with acyclovir. *N Engl J Med* 1982; 306: 343-6.
128. Coen DM. Acyclovir-resistant herpes simplex virus. *N Engl J Med* 1982; 307: 681-2.
129. Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, Grant RM, Crumacker CS. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. *N Engl J Med* 1989; 320: 290-6.
130. Parris DS, Harrington JE. Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates. *Antimicrob Agents Chemother* 1992; 22: 71-7.
131. Pottage JC, Kesster HA. Herpes simplex virus resistance to acyclovir: clinical relevance. *Infect Agents Dis* 1995; 4: 115-24.
132. Hodinka RL. What Clinicians need to know about antiviral drugs and viral resistance. *Infect Dis Clin North Am* 1997; 11: 945-67.

133. Safrin S, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. *Antimicrob Agents Chemother* 1994; 38: 1246-50.
134. Leary JJ, Wittrock R, Sarisky RT, Weinberg A, Levin MJ. Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. *Antimicrob Agents Chemother* 2002; 46: 762-8.
135. Sarisky RT, Drosson P, Cano R, et al. Comparison of methods for identifying resistant herpes simplex virus and measuring antiviral susceptibility. *J Clin Virol* 2002; 23: 191-200.
136. Sande M, Armstrong D, Corey L, et al. Perspectives on a switch of oral acyclovir from prescription to over-the-counter status: report of a consensus panel. *Clin Infect Dis* 1998; 26: 659-63.
137. Bacon TH, Boon RJ, Schultz M, Hodges-Savola C. Surveillance for antiviral-agent-resistant herpes simplex virus in the general population with recurrent herpes labialis. *Antimicrob Agents Chemother* 2002; 46: 3042-4.
138. Boon RJ, Bacon TH, Robey HL, et al. Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialis: a UK based study. *J Antimicrob Chemother* 2000; 46: 324-5.
139. Collins P, Eills MN. Sensitivity monitoring of clinical; isolates of herpes simplex virus to acyclovir. *J Med Virol* 1993; (suppl1): 58-66.

140. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. The acyclovir study group recurrence and resistance patterns of herpes simplex virus following cessation of > 6 years of chronic suppression with acyclovir. *J Infect Dis* 1994; 169: 1339- 41.
141. Mouly F, Baccard M, Scieux C, et al. Chronic recurrent acyclovir-resistant genital herpes in an immunocompetent patient. *Dermatology* 1995; 190; 177.
142. Swetter SM, Hill EL, Kern ER, et al. Chronic vulva ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus. *J Infect Dis* 1998; 177: 543-550.
143. Chen Y, Scieux C, Garrait V, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogenic stem cell transplantation. *Clin Infect Dis* 2000; 31: 927-35.
144. Wade JC, McLaren C, Meyers JD. Frequency and significance of acyclovir-resistant herpes simplex isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. *J Intect Dis* 1983; 148: 1077-82.
145. Whitley RJ, Levin M, Barton N, et al. Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical therapy. *J Intect Dis* 1984; 150: 323-9.
146. Burns WH, Saral R, Santos GW, Laskin OL, Leitman PS. Isolation and characterization of resistant herpes simplex virus after acyclovir therapy. *Lancet* 1982; i: 421-3.
147. Pittayathikhun K, Korkij W, Punnarugsa V, Bhattarakosol P. Viral isolation in different herpes labials by shell viral centrifugation cell culture. *Chula Med J* 1995; 39 (8): 593-9.

148. The homepage of TML\MSH. Microbiology department policy & procedure manual policy.2001 March 14. Shell viral produce. [ONLINE]
<http://microbiology.mtsinai.onca/manual/pdfs/virology.pdf> (visited 05/02/03).
149. Lecomte J. Immunofluorescence. In: Payment P, Trudel M, eds. *Methods and techniques in virology*. 1st ed. New York : MARCEL DEKKER, 1993: 129-6.
150. Chu P, Edberg S, Konthick C, et al. Detecting resistance of herpes simplex viral to antiviral agents. *Lab News* 1996 Feb; 38 (1).
151. Darby, G. In search of the perfect antiviral. *Antiviral Chemother* 1995; 6 (Suppl): 54-63.
152. Pavic I, Hartmann A, Zimmermann A, et al. Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir, and foscarnet. *Antimicrob Agents Chemother* 1997 Dec; 41(12): 2686-92.
153. Nahmias AJ, Dowdie WR, Naib ZM, et al. Genital infection with type 2 herpes virus hominis. A commonly occurring venereal disease. *Br J Vener Dis* 1969; 45: 294-8.
154. Cheong WK, Thiurumoorthy T, Doraisingam S, et al. Clinical and laboratory study of first episode genital herpes in Singapore. *Int J STD AIDS* 1990; 1: 195-8.
155. Lavery HA, Connolly JH, Russell JD. Incidence of herpes simplex in Northern Ireland in 1973-83 and herpes simplex types 1 and 2 isolated in 1982-4. *Genitourin Med* 1986; 62: 24-7.
156. Lowhagen GB, Jensen E, Nordenfelt E, et al. Epidemiology of genital herpes in Sweden. *Acta Derm Venereol (Stockh)* 1990; 70: 330-4.

157. Wooley PD, Kudesia G. Incidence of herpes in Sheffield. *Int J STD AIDS* 1990; 1: 184-6.
158. Lowhagen G-B, Tunback P, Andersson K, Bergstrom T, Johannisson G. First episodes of genital herpes in Swedish STD population: a study of epidemiology by the use of herpes simplex virus (HSV) typing and specific serology. *Sex Transm Infect* 2000; 76: 176-82.
159. Lippeit L, Braun RW, Kuhn JE. Genital herpes simplex virus type 1 infection: new fields for an old acquaintance?. *Intervirology* 2000; 45(1): 2-5.
160. Rodger CA. High prevalence of herpes simplex virus type 1 in female and genital herpes. *Int J STD AIDS* 1995; 6: 144-6.
161. Christie SN, McCaughey C, McBride M, et al. Herpes simplex type 1 and genital herpes in Northern Ireland. *Int J STD AIDS* 1997; 8: 68-70.
162. Thompson C. Genital herpes simplex typing in genitourinary medicine: 1995-1999. *Int J STD AIDS* 1997 Aug; 11(8): 501-2.
163. Yoosook C, Chantratita W, Rimdusit P. Recovery frequencies of herpes simplex virus types 1 and 2 from symptomatic and asymptomatic genital herpes cases and antiviral sensitivities of isolates. *J Med Assoc Thai* 1989 Oct; 72(10): 572-7.
164. Puthavathana P, Wasi C, Bhirleus P, Kanyok R, Ekpatch N, Thogcharoen P. Typing herpes simplex isolates at Siriraj Hospital, Bangkok Thailand. *Virus Information Exchange Newsletter* 1991; 8: 125.

165. Puthavathana P, Kanyok R, Horthongkham N, Roongpisuthipong A. Prevalence of herpes simplex virus typing by type specific fluorescent monoclonal antibodies. *J Med Assoc Thai* 1998 Apr; 81(4): 260-4.
166. Nicolosi A, Correa Leite ML, Musicco M, et al. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency transmission. *Epidemiology* 1994; 5: 570-5.
167. Sucato G, Wald A, Wakabayashi E, Vieira J, Corey L. Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region. *J Infect Dis* 1998 Apr; 177(4): 1069-72.
168. Lipipun V, Rasmi A, Pengsuparp T, Sutrisri R. Antiviral activity against herpes simplex virus type of extracts from *Phyla Nodiflora* (L.) Greene. *J Med Tech Assoc Thailand* 2000 Dec; 28(2): 46-51.
169. Christophers J, Sutton RNP. Characterization of acyclovir-resistant and sensitive clinical herpes simplex virus isolates from an immunocompromised patient. *N Engl J Med* 1987; 20: 389-98.
170. Christophers J, Noble RV, Anderson H. Clinical resistance to acyclovir of herpes simplex virus infections in immunocompromised patients. *N Engl J Med* 1986; 18 (Suppl B): 121-5.
171. Collins P. Viral sensitivity following the introduction of acyclovir. *American J Med* 1988; 85(Suppl 2B): 129-34.
172. Field HJ. Persistent herpes simplex virus infection and mechanisms of virus drug resistance. *Euro J Clin Microb Inf Dis* 1989; 8: 671-80.



APPENDICES

ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย

APPENDIX I

REAGENTS, MATERIALS, AND INSTRUMENTS

A. MEDIA AND REAGENTS

Acetone	(Merck, Germany)
Acyclovir (Acycloguanosine)	(Sigma, U.S.A.)
Bovine Serum Albumin	(Sigma, U.S.A.)
Fetal bovine serum (FBS)	(GIBCO BRL, U.S.A.)
FITC-conjugated (Fab') ₂ fragment of goat antimouse immunoglobulins (F 0479)	(DAKOAS, Denmark)
Gum tragacanth	(Sigma, U.S.A.)
L-glutamine	(Sigma, U.S.A.)
Medium 199 (M199)	(GIBCO BRL, U.S.A.)
Monoclonal HSV-1 or HSV-2 type specific (NCL-HSV-1, HSV-2)	(NOVO cratra laboratory Ltd, United Kingdom)
N ₂ -hydroxyethylpiperazine-N' ₂ -ethanesulphonic acid (HERPES)	(Sigma, U.S.A.)
Penicillin G- Streptomycin	(GIBCO BRL, U.S.A.)
Potassium chloride (KCl)	(Merck, Germany)
Sodium chloride (NaCl)	(Merck, Germany)

Sodium hydrogencarbonate (NaHCO_3)	(Merck, Germany)
Trypsin	(Sigma, U.S.A.)

B. MATERIALS

Microcentrifuge tube	(SRS, U.S.A.)
Tissue culture flask	(Nunclon, Denmark)
Tissue culture plate	(Nunclon, Denmark)

C. INSTRUMENTS

Autoclave (model S-90N)	(Tomy Seiko, Japan)
Fluorescence Microscope (Olympus BH-2-RFL-T3)	(Olympus optical Co,LTD, Japan)
Fluorescence Microscope with mercury lamp (Olympus PM-20)	(Olympus optical Co, Ltd, Japan)
Incubator type 80	(Memmert, Germany)
Inverted Microscope (CK ₂)	(Olympus optical Co, Ltd, Japan)
Microcentrifuge (MicroCen 13)	(Herolab, Germany)
Mixer-Vertex-Genie (K55O-GE)	(Scientific industries, U.S.A.)

Photography camera (Olympus U-ULH, BX50)	(Olympus optical Co, Ltd, Japan)
Refrigerator	(Toshiba, Japan)
Water bath (EM)	(Julabo, Germany)



ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย

APPENDIX II

REAGENTS PREPARATION

1. 10% M199 medium

2X M199 with Earle's salts, with L-glutamine, without NaHCO ₃	50	ml
1M HEPES	1	ml
Pen/Strep. Antibiotic (10 ⁵ unit/ml)	0.1	ml
10% NaHCO ₃	1	ml
5% L-glutamine	1	ml
FBS	10	ml
DDW (sterile)	46	ml
Stored at 4 ^o C		

2. 10X PBS (phosphate buffer saline)

NaCl	40	g
KCL	1	g
NaHPO ₄	5.75	g
KH ₂ PO ₄	1	g
DDW	300	ml

Adjusted to pH 7.4 and adjusted volume to 500 ml with DDW and sterilized by autoclaving

3. 1X PBS

10X stock PBS	100	ml
DDW (sterile)	900	ml

4. 10X Trypsin

Trypsin	0.5	g
EDTA	0.2	g
NaCl	9.0	g
DDW	100	ml

Sterilized by filtration and stored at -20°C

5. 1X Trypsin

10X stock trypsin	10	ml
DDW (sterile)	90	ml

Stored at 4°C

6. Plaque overlay medium

Solution A

10X M199 with Earle's salts, with L-glutamine		
without NaHCO ₃	20	ml
FBS	20	ml
1 M HEPES	2	ml
Pen/Strep. Antibiotic (10 ⁵ unit/ml)	0.2	ml
10% NaHCO ₃	3	ml
5% L-glutamine	2	ml
DDW	42	ml

Solution B

Gum tragacanth	1.6	ml
DDW	100	ml

Sterile by autoclaving

Prepare solution A : solution B 1:1 before use

BIOGRAPHY

Miss Ajchariyarat Sangdara was born on February 10, 1977 in Nakornsawan, Thailand. She received the degree of Bachelor of Microbiology of Science in 1999 from Faculty of Science, Burapha University, Chonburi, Thailand.



ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย